← back to search

David W. Hutton

University of Bristol · US
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Hepatitis B Virus Studies, Hepatitis C virus research, Retinal and Optic Conditions, and Health Systems, Economic Evaluations, Quality of Life.
h-index
37
citations
10,839
works
234
NIH funding
primary concept
Medicine
email

Recent publications

The burden of Chronic Pelvic Pain (CPP): Costs and quality of life of women and men with CPP treated in outpatient referral centers
PLoS ONE 2023cited by 30position: firstdoi
Gaps in Prenatal Hepatitis B Screening and Management of HBsAg Positive Pregnant Persons in the U.S., 2015–2020
American Journal of Preventive Medicine 2023cited by 27position: middledoi
Gaps and Disparities in Chronic Hepatitis B Monitoring and Treatment in the United States, 2016-2019
Medical Care 2023cited by 20position: middledoi
Impact of the national hepatitis B immunization program in China: a modeling study
Infectious Diseases of Poverty 2022cited by 42position: middledoi
Costs and health impact of delayed implementation of a national hepatitis B treatment program in China
Journal of Global Health 2022cited by 8position: middledoi
Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States
Clinical Infectious Diseases 2021cited by 70position: middledoi
The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia
Liver International 2021cited by 13position: middledoi
Introduction to the special issue: Management Science in the Fight Against Covid-19
Health Care Management Science 2021cited by 8position: middledoi
Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States
Hepatology 2021cited by 6position: middledoi
Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income
Value in Health 2020cited by 24position: middledoi
Hepatitis B cure: modeling the economics of a potential cost of a cure
Current Opinion in HIV and AIDS 2020cited by 5position: lastdoi
Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30
The Lancet Global Health 2019cited by 99position: middledoi
Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma
Liver International 2019cited by 50position: middledoi
The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment
˜The œLancet. Gastroenterology & hepatology 2019cited by 4position: middledoi
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment
JAMA Ophthalmology 2016cited by 210position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mehlika Toy · Palo Alto University10 papers (2019–2023)Samuel So · Palo Alto University8 papers (2019–2023) · 3 papers (2019–2020)Joshua A. Salomon · Stanford University3 papers (2021–2023) · 3 papers (2019–2020)Noele P. Nelson · Cornell University3 papers (2021–2023)Marc Bulterys · Gates Foundation2 papers (2019–2019)Erin E. Conners · Centers for Disease Control and Prevention2 papers (2023–2023)Karin Stenberg · Sunderby sjukhus2 papers (2019–2020)Thi T. Hang Pham · Palo Alto University2 papers (2023–2023) · 2 papers (2019–2020)Nick Scott · Burnet Institute2 papers (2019–2020)David Tordrup · Utrecht University2 papers (2019–2020)Joshua Epstein · University of Colorado Denver1 papers (2023–2023)Robert G. Gish · Southern Medical University1 papers (2021–2021) · 1 papers (2023–2023) · 1 papers (2021–2021)Timothy M. Block · Drexel University1 papers (2021–2021)Nimisha Maria · Palo Alto University1 papers (2023–2023) · 1 papers (2021–2021)